Editorial
The (un)lucky seven—how can we mitigate risk factors for postoperative pneumonia after lung resections?
Translational Lung Cancer Research
2024;
13
(8)
:1763-1767
.
(31 August 2024)
Original Article
Redefining YAP1 in small cell lung cancer: shifting from a dominant subtype marker to a favorable prognostic indicator
Translational Lung Cancer Research
2024;
13
(8)
:1768-1779
.
(31 August 2024)
Identifying genetically-supported drug repurposing targets for non-small cell lung cancer through mendelian randomization of the druggable genome
Translational Lung Cancer Research
2024;
13
(8)
:1780-1793
.
(31 August 2024)
CT-based radiomic consensus clustering association with tumor biological behavior in clinical stage IA adenocarcinoma: a retrospective study
Translational Lung Cancer Research
2024;
13
(8)
:1794-1806
.
(31 August 2024)
Safety and efficacy of immunotherapy using a double-dose regimen in advanced non-small cell lung cancer (NSCLC): results of IDEE study
Translational Lung Cancer Research
2024;
13
(8)
:1807-1815
.
(31 August 2024)
LungPath: artificial intelligence-driven histologic pattern recognition for improved diagnosis of early-stage invasive lung adenocarcinoma
Translational Lung Cancer Research
2024;
13
(8)
:1816-1827
.
(31 August 2024)
Radiogenomics models for predicting prognosis in locally advanced non-small cell lung cancer patients undergoing definitive chemoradiotherapy
Translational Lung Cancer Research
2024;
13
(8)
:1828-1840
.
(31 August 2024)
A nomogram predicting the risk of extrathoracic metastasis at initial diagnosis of T≤3cmN0 lung cancer
Translational Lung Cancer Research
2024;
13
(8)
:1841-1850
.
(31 August 2024)
Effect of family history of cancer on postoperative survival in patients with non-small cell lung cancer
Translational Lung Cancer Research
2024;
13
(8)
:1851-1861
.
(31 August 2024)
Evaluation of the novel International Association for the Study of Lung Cancer grading system in adenocarcinoma with spread through air space
Translational Lung Cancer Research
2024;
13
(8)
:1862-1876
.
(31 August 2024)
Knowledge and beliefs about lung cancer screening among Black individuals at high risk: a qualitative approach
Translational Lung Cancer Research
2024;
13
(8)
:1877-1887
.
(31 August 2024)
Prognostic and predictive significance of soluble programmed death ligand 1 in bronchoalveolar lavage fluid in stage IV non-small cell lung cancer
Translational Lung Cancer Research
2024;
13
(8)
:1888-1906
.
(31 August 2024)
Assessing the transportability of radiomic models for lung cancer diagnosis: commercial vs. open-source feature extractors
Translational Lung Cancer Research
2024;
13
(8)
:1907-1917
.
(31 August 2024)
Emphysema and lung cancer risk
Translational Lung Cancer Research
2024;
13
(8)
:1918-1928
.
(31 August 2024)
CYFRA 21-1 predicts efficacy of combined chemoimmunotherapy in patients with advanced non-small cell lung cancer: a prospective observational study
Translational Lung Cancer Research
2024;
13
(8)
:1929-1937
.
(31 August 2024)
Clinical features and prognostic biomarkers in patients with SMARCA4-mutated non-small cell lung cancer
Translational Lung Cancer Research
2024;
13
(8)
:1938-1949
.
(31 August 2024)
Efficacy and prognostic factors of stereotactic body radiotherapy combined with immunotherapy for pulmonary oligometastases: a preliminary retrospective cohort study
Translational Lung Cancer Research
2024;
13
(8)
:1950-1963
.
(31 August 2024)
Effective induction immunotherapy minimizes surgical invasiveness for locally advanced lung cancer
Translational Lung Cancer Research
2024;
13
(8)
:1964-1974
.
(31 August 2024)
Prognostic role of dynamic changes in inflammatory indicators in patients with non-small cell lung cancer treated with immune checkpoint inhibitors—a retrospective cohort study
Translational Lung Cancer Research
2024;
13
(8)
:1975-1987
.
(31 August 2024)
Single-center clinical experience of extended sleeve lobectomy (ESL) versus standard sleeve lobectomy (SL)
Translational Lung Cancer Research
2024;
13
(8)
:1988-1999
.
(31 August 2024)
Enhanced tumor targeting and penetration of fluorophores via iRGD peptide conjugation: a strategy for the precision targeting of lung cancer
Translational Lung Cancer Research
2024;
13
(8)
:2000-2014
.
(31 August 2024)
Efficacy of ALK inhibitors in Asian patients with ALK inhibitor-naïve advanced ALK-positive non-small cell lung cancer: a systematic review and network meta-analysis
Translational Lung Cancer Research
2024;
13
(8)
:2015-2022
.
(31 August 2024)
Neutrophil estimation and prognosis analysis based on existing lung squamous cell carcinoma datasets: the development and validation of a prognosis prediction model
Translational Lung Cancer Research
2024;
13
(8)
:2023-2037
.
(31 August 2024)
Case Report
Successful carinal reconstruction with right main bronchial flap rotational embedded augmentation: a case report
Translational Lung Cancer Research
2024;
13
(8)
:2038-2042
.
(31 August 2024)
Immune-related osteoblastic bone alterations mimicking bone metastasis in a small-cell lung cancer patient treated with durvalumab: a case report
Translational Lung Cancer Research
2024;
13
(8)
:2043-2049
.
(31 August 2024)
Review Article
Oncogene-addicted solid tumors and microbiome—lung cancer as a main character: a narrative review
Translational Lung Cancer Research
2024;
13
(8)
:2050-2066
.
(31 August 2024)
Research into overcoming drug resistance in lung cancer treatment using CRISPR-Cas9 technology: a narrative review
Translational Lung Cancer Research
2024;
13
(8)
:2067-2081
.
(31 August 2024)
Editorial Commentary
REGN5093-M114: can an antibody-drug conjugate overcome the challenge of resistance to epidermal growth factor receptor and mesenchymal epithelial transition tyrosine kinase inhibitors in non-small cell lung cancer?
Translational Lung Cancer Research
2024;
13
(8)
:2082-2086
.
(31 August 2024)
Are PD-1T TILs merely an expensive and unuseful whim as biomarker?
Translational Lung Cancer Research
2024;
13
(8)
:2087-2090
.
(31 August 2024)
Can a dysfunctional T-cell gene signature predict nonresponse to PD-1 blockade in non-small cell lung cancer?
Translational Lung Cancer Research
2024;
13
(8)
:2091-2094
.
(31 August 2024)
Clinical insights: five-year follow-up of KEYNOTE-189 trial outcomes and more
Translational Lung Cancer Research
2024;
13
(8)
:2095-2097
.
(31 August 2024)
Breaking barriers: patient-derived xenograft (PDX) models in lung cancer drug development—are we close to the finish line?
Translational Lung Cancer Research
2024;
13
(8)
:2098-2102
.
(31 August 2024)
